Cargando…
A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer
Circulating tumour cells (CTCs) from liquid biopsies are under current investigation in several cancers, including epithelial ovarian cancer (EOC) but face significant drawbacks in terms of non-standardised methodology, low viable cell numbers and accuracy of CTC identification. In this pilot study,...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370156/ https://www.ncbi.nlm.nih.gov/pubmed/32646060 http://dx.doi.org/10.3390/ijms21134813 |
_version_ | 1783560934034243584 |
---|---|
author | Guadagni, Stefano Clementi, Marco Masedu, Francesco Fiorentini, Giammaria Sarti, Donatella Deraco, Marcello Kusamura, Shigeki Papasotiriou, Ioannis Apostolou, Panagiotis Aigner, Karl Reinhard Zavattieri, Giuseppe Farina, Antonietta Rossella Vizzielli, Giuseppe Scambia, Giovanni Mackay, Andrew Reay |
author_facet | Guadagni, Stefano Clementi, Marco Masedu, Francesco Fiorentini, Giammaria Sarti, Donatella Deraco, Marcello Kusamura, Shigeki Papasotiriou, Ioannis Apostolou, Panagiotis Aigner, Karl Reinhard Zavattieri, Giuseppe Farina, Antonietta Rossella Vizzielli, Giuseppe Scambia, Giovanni Mackay, Andrew Reay |
author_sort | Guadagni, Stefano |
collection | PubMed |
description | Circulating tumour cells (CTCs) from liquid biopsies are under current investigation in several cancers, including epithelial ovarian cancer (EOC) but face significant drawbacks in terms of non-standardised methodology, low viable cell numbers and accuracy of CTC identification. In this pilot study, we report that chemosensitivity assays using liquid biopsy-derived metastatic EOC CTCs, from 10 patients, nine with stage IIIC and one with stage IV disease, in progression after systemic chemotherapy, submitted for hypoxic isolated abdominal perfusion (HAP), are both feasible and useful in predicting response to therapy. Viable metastatic EOC CTCs (>5 cells/mL for all 10 blood samples), enriched by transient culture and identified by reverse transcription polymerase chain reaction (RT-PCR) and indirect immunofluorescence (IF), were subjected to flow cytometry-based Annexin V-PE assays for chemosensitivity to several chemotherapeutic agents and by RT-PCR for tumour gene expression profiling. Using a cut-off value of >80% cell death, CTC chemosensitivity tests were predictive of patient RECIST 1.1 responses to HAP therapy associated with 100% sensitivity, 50% specificity, 33% positive predictive, 100% negative predictive and 60% accuracy values. We propose that the methodology employed in this study is feasible and has the potential to predict response to therapy, setting the stage for a larger study. |
format | Online Article Text |
id | pubmed-7370156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73701562020-07-21 A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer Guadagni, Stefano Clementi, Marco Masedu, Francesco Fiorentini, Giammaria Sarti, Donatella Deraco, Marcello Kusamura, Shigeki Papasotiriou, Ioannis Apostolou, Panagiotis Aigner, Karl Reinhard Zavattieri, Giuseppe Farina, Antonietta Rossella Vizzielli, Giuseppe Scambia, Giovanni Mackay, Andrew Reay Int J Mol Sci Article Circulating tumour cells (CTCs) from liquid biopsies are under current investigation in several cancers, including epithelial ovarian cancer (EOC) but face significant drawbacks in terms of non-standardised methodology, low viable cell numbers and accuracy of CTC identification. In this pilot study, we report that chemosensitivity assays using liquid biopsy-derived metastatic EOC CTCs, from 10 patients, nine with stage IIIC and one with stage IV disease, in progression after systemic chemotherapy, submitted for hypoxic isolated abdominal perfusion (HAP), are both feasible and useful in predicting response to therapy. Viable metastatic EOC CTCs (>5 cells/mL for all 10 blood samples), enriched by transient culture and identified by reverse transcription polymerase chain reaction (RT-PCR) and indirect immunofluorescence (IF), were subjected to flow cytometry-based Annexin V-PE assays for chemosensitivity to several chemotherapeutic agents and by RT-PCR for tumour gene expression profiling. Using a cut-off value of >80% cell death, CTC chemosensitivity tests were predictive of patient RECIST 1.1 responses to HAP therapy associated with 100% sensitivity, 50% specificity, 33% positive predictive, 100% negative predictive and 60% accuracy values. We propose that the methodology employed in this study is feasible and has the potential to predict response to therapy, setting the stage for a larger study. MDPI 2020-07-07 /pmc/articles/PMC7370156/ /pubmed/32646060 http://dx.doi.org/10.3390/ijms21134813 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Guadagni, Stefano Clementi, Marco Masedu, Francesco Fiorentini, Giammaria Sarti, Donatella Deraco, Marcello Kusamura, Shigeki Papasotiriou, Ioannis Apostolou, Panagiotis Aigner, Karl Reinhard Zavattieri, Giuseppe Farina, Antonietta Rossella Vizzielli, Giuseppe Scambia, Giovanni Mackay, Andrew Reay A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer |
title | A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer |
title_full | A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer |
title_fullStr | A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer |
title_full_unstemmed | A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer |
title_short | A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer |
title_sort | pilot study of the predictive potential of chemosensitivity and gene expression assays using circulating tumour cells from patients with recurrent ovarian cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370156/ https://www.ncbi.nlm.nih.gov/pubmed/32646060 http://dx.doi.org/10.3390/ijms21134813 |
work_keys_str_mv | AT guadagnistefano apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT clementimarco apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT masedufrancesco apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT fiorentinigiammaria apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT sartidonatella apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT deracomarcello apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT kusamurashigeki apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT papasotiriouioannis apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT apostoloupanagiotis apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT aignerkarlreinhard apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT zavattierigiuseppe apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT farinaantoniettarossella apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT vizzielligiuseppe apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT scambiagiovanni apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT mackayandrewreay apilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT guadagnistefano pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT clementimarco pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT masedufrancesco pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT fiorentinigiammaria pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT sartidonatella pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT deracomarcello pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT kusamurashigeki pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT papasotiriouioannis pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT apostoloupanagiotis pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT aignerkarlreinhard pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT zavattierigiuseppe pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT farinaantoniettarossella pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT vizzielligiuseppe pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT scambiagiovanni pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer AT mackayandrewreay pilotstudyofthepredictivepotentialofchemosensitivityandgeneexpressionassaysusingcirculatingtumourcellsfrompatientswithrecurrentovariancancer |